Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Quadro-iliac plane block, Erector spinae plane block.
- Who it may be relevant to
- Registry conditions: Analgesic Efficacy, Quadro-Iliac Plane Block, Erector Spinae Plane Block, Total Hip Arthroplasty. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty: A Randomized Non-Inferiority Trial
Overview
This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.
Detailed description
Total hip arthroplasty (THA) is frequently utilized in elderly patients to address hip pain and restore joint function. Effective postoperative pain management is critical; however, the use of opioids is associated with a range of adverse effects, including nausea, vomiting, pruritus, constipation, respiratory depression, and the risk of dependence.
Quadro-iliac plane block (QIPB) has been introduced, combining elements of both posterior and anterior QLB approaches.
Erector Spinae Plane Block (ESPB) was initially described as an analgesic approach for managing thoracic neuropathic pain. This innovative fascial block technique enables sensory blockade across multiple abdominal and thoracic wall segments.
Interventions
- Other Quadro-iliac plane block
Patients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%. - Other Erector spinae plane block
Patients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%.
Primary outcome measures
- Time to the first rescue analgesia [Time frame: 24 hours postoperatively]
Secondary outcome measures (4)
- Total morphine consumption [Time frame: 24 hours postoperatively]
- Degree of pain [Time frame: 24 hours postoperatively]
- Quality of recovery [Time frame: 24 hours postoperatively]
- Incidence of adverse events [Time frame: 24 hours postoperatively]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-III.
- Undergoing total hip arthroplasty (THA) under spinal anesthesia.
Exclusion criteria
- History of allergies to local anesthetics.
- Opioid dependency.
- Body mass index (BMI) > 35 kg/m2.
- Cognitive impairment.
- Bleeding or coagulation disorders.
- Psychiatric and neurological disorder.
- Local infection at the site of injection.
- Severe heart, lung, liver, and renal dysfunction.
- Emergency surgery.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT07537036 · 36264PR131011044/3/26